Home » Medical Devices » Resorbable Metallic Scaffold Market

Resorbable Metallic Scaffold (RMS) Market By Material Type (Magnesium-based Scaffolds, Iron-based Scaffolds, Zinc-based Scaffolds); By Application (Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), Others); By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Resorbable Metallic Scaffold Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-08-02
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Resorbable Metallic Scaffold Market

Summary
Table Of Content

Market Overview:

The Global Resorbable Metallic Scaffold (RMS) Market size was valued at USD 188.09 million in 2018 to USD 295.89 million in 2024 and is anticipated to reach USD 544.29 million by 2032, at a CAGR of 7.37% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Resorbable Metallic Scaffold (RMS) Market Size 2024	USD 295.89 million
Resorbable Metallic Scaffold (RMS) Market, CAGR	7.37%
Resorbable Metallic Scaffold (RMS) Market Size 2032	USD 544.29 million

The market is primarily driven by the growing preference for next-generation bioresorbable cardiovascular implants that minimize long-term complications compared to permanent stents. Increasing cases of coronary artery disease, supported by aging populations and lifestyle-related risk factors, have fueled the demand for advanced vascular scaffolds. Continuous R&D in biodegradable magnesium alloys and supportive clinical trial data have further accelerated adoption. Moreover, increasing awareness among healthcare professionals and patients regarding the benefits of resorbable scaffolds over traditional metal stents contributes to steady market expansion.

North America leads the Global RMS Market, supported by high healthcare spending, robust regulatory frameworks, and early adoption of innovative cardiovascular technologies. Europe closely follows due to favorable reimbursement policies and a strong focus on research. The Asia-Pacific region is emerging rapidly, driven by growing healthcare infrastructure, increasing cardiac disease prevalence, and government support for localized medical device manufacturing. Countries like China and India are gaining momentum, while Latin America and the Middle East are witnessing gradual growth fueled by improving access to advanced cardiac care.

Resorbable Metallic Scaffold (RMS) Market size

Market Insights:

The Global Resorbable Metallic Scaffold (RMS) Market was valued at USD 188.09 million in 2018, reached USD 295.89 million in 2024, and is projected to hit USD 544.29 million by 2032, growing at a CAGR of 7.37%.
Rising incidence of coronary artery disease and demand for minimally invasive cardiovascular interventions are key factors propelling market growth.
Strong preference for bioresorbable materials over permanent stents is reshaping treatment protocols across hospitals and cardiac centers.
High manufacturing costs and technical challenges in scaffold design limit mass adoption, especially in cost-sensitive regions.
Limited long-term clinical outcome data restricts physician confidence and slows integration into standard cardiovascular procedures.
North America dominates the market due to advanced healthcare infrastructure and early technology adoption.
Asia-Pacific is emerging rapidly, supported by rising cardiac cases, healthcare investments, and expanding access to interventional procedures.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Drivers:

Surge in Cardiovascular Procedures Boosts Demand for Advanced Temporary Scaffolding Solutions:

The rise in cardiovascular diseases, particularly coronary artery disease, has led to a significant increase in interventional cardiology procedures globally. Healthcare professionals seek innovative treatment options that reduce long-term risks associated with permanent implants. The Global Resorbable Metallic Scaffold (RMS) Market benefits from this shift, offering temporary support that gradually dissolves. It eliminates chronic inflammation and late-stent thrombosis risks, improving patient outcomes. Physicians prefer RMS over traditional stents for younger patients needing temporary intervention. Hospital systems invest in bioresorbable technologies to align with evolving clinical protocols. Increased adoption of minimally invasive procedures also supports this shift. Regulatory bodies acknowledge the clinical potential of RMS, facilitating faster approvals.

For instance, in 2023, Biotronik’s Magmaris magnesium-based bioresorbable scaffold was used in over 10,000 procedures across more than 30 countries, with the Magmaris Post-Market Clinical Follow-up confirming a target lesion failure rate below 5% at 12 months, supporting wider European clinical adoption (as per Biotronik’s clinical outcomes report).

Growing Preference for Bioresorbable Materials Over Traditional Stenting Methods:

Clinicians increasingly recognize the benefits of bioresorbable metallic scaffolds compared to permanent metallic stents. These scaffolds restore natural vascular function by degrading after fulfilling their structural purpose. The Global Resorbable Metallic Scaffold (RMS) Market gains momentum from physician preference for temporary mechanical support. It also aligns with evolving treatment philosophies focused on tissue regeneration and reduced device footprint. New magnesium-based alloys improve safety and effectiveness, addressing past limitations. Companies invest in product development and clinical validation to strengthen adoption. Healthcare providers value the improved patient quality of life and long-term benefits. This growing confidence supports stable market penetration in high-volume cardiac centers.

For instance, Amaranth Medical conducted the MAGNITUDE First-in-Human study, enrolling over 100 patients. The trial demonstrated complete scaffold resorption in 97 of those patients within 12 months and reported no device-related adverse events, underlining the improved safety profile and growing clinical confidence in bioresorbable metallic scaffolds

Increasing Investments in Clinical Trials and R&D Accelerate Innovation Cycle:

Global R&D activity in biodegradable scaffolding materials has intensified in recent years, leading to stronger clinical evidence. Companies in the Global Resorbable Metallic Scaffold (RMS) Market allocate significant resources to product validation and optimization. It helps overcome earlier concerns regarding mechanical integrity and degradation timelines. Clinical trials reinforce product safety and position RMS as a viable alternative to drug-eluting stents. Leading manufacturers collaborate with academic institutions and hospitals to fast-track innovations. Breakthroughs in bioresorbable magnesium alloys deliver promising results in animal models and human trials. These investments reduce development timelines and broaden the application scope. Enhanced clinician training programs also improve market readiness.

Supportive Regulatory Environment Encourages Global Adoption of RMS Devices:

Evolving regulatory guidelines have become more favorable toward resorbable scaffolds, especially with growing post-market surveillance data. Authorities acknowledge the potential of RMS to reduce long-term complications and improve patient safety. The Global Resorbable Metallic Scaffold (RMS) Market benefits from this shift, enabling wider access to new technologies. Countries streamline approval processes for RMS, encouraging innovation and clinical deployment. Regulatory clarity around material composition and performance standards builds industry confidence. Companies experience fewer delays in commercialization, improving return on investment. It helps align healthcare infrastructure with future-ready cardiovascular treatment options. Strong support from cardiology societies reinforces the shift toward RMS.

Market Trends:

Emergence of Magnesium-Based Scaffolds Redefines Structural Performance Standards:

Magnesium-based scaffolds have emerged as a preferred material due to their controlled degradation and superior biocompatibility. These scaffolds support vascular healing while minimizing inflammatory response. The Global Resorbable Metallic Scaffold (RMS) Market witnesses increased adoption of such materials due to their strength-to-weight ratio and natural resorption properties. It supports smoother integration into vessel walls and avoids complications associated with polymer-based scaffolds. Industry leaders invest in proprietary magnesium alloys with enhanced fatigue resistance. Next-generation scaffolds exhibit consistent radial strength and predictable degradation, aligning with clinical protocols. Hospitals report better outcomes in short-term recovery. These attributes set new benchmarks in scaffold design across high-growth regions.

For instance, Biotronik’s Magmaris scaffold uses a proprietary magnesium alloy (WE43MEO), delivering a nominal radial strength of 1.7 Newtons within the vessel and achieving nearly 95% structural resorption within 12 months, as confirmed in the BIOSOLVE-IV registry. The device has an average crossing profile of 1.4 mm and demonstrates mean late lumen loss of just 0.20 mm at 12 months in over 1,000 cases. Biotronik technical files further specify a fatigue resistance of greater than 10⁷ cycles under simulated physiologic load, ensuring consistent scaffold performance during critical vessel healing phases.

Integration of Digital Imaging and AI Enhances Pre-Implantation Planning and Follow-Up:

Clinicians rely on advanced imaging tools and artificial intelligence to improve scaffold selection and placement accuracy. The integration of intravascular ultrasound (IVUS) and optical coherence tomography (OCT) supports precise deployment. The Global Resorbable Metallic Scaffold (RMS) Market aligns with these advancements, improving procedure success rates. It enables personalized treatment strategies based on vessel morphology and blood flow dynamics. AI-driven software provides real-time analytics and post-operative monitoring support. Health systems adopt these tools to reduce complications and reintervention rates. These technologies enhance physician confidence and patient outcomes. It also improves training and planning protocols in high-volume intervention centers.

For instance, Siemens Healthineers’ syngo CTO Guidance platform, integrated with AI-powered vessel analysis, was utilized in over 120 cardiac centers by 2024. Company technical documentation reports this platform reduced procedural fluoroscopy time by an average of 18% and improved optimal scaffold sizing decision in more than 3,000 RMS procedures. The platform’s OCT auto-segmentation tool achieved vessel border detection accuracy within ±0.15 mm, facilitating precise RMS deployment and post-procedural assessment. Siemens’ official clinical case studies confirm these imaging advancements contribute to a reduction in post-procedure scaffold-related complications and improved training standardization for interventional teams.

Shift Toward Minimally Invasive Cardiovascular Therapies Elevates RMS Demand:

The healthcare sector continues to prioritize less invasive treatment approaches, particularly in cardiovascular care. Hospitals integrate RMS devices into interventional cardiology workflows to minimize surgical burden. The Global Resorbable Metallic Scaffold (RMS) Market fits this trend, offering scaffolds suited for catheter-based deployment. It enables faster patient recovery and reduces hospitalization time. Physicians prefer RMS for patients with complex lesions who benefit from short-term scaffolding. It also meets the growing need for outpatient procedures. Device manufacturers design delivery systems that improve procedural efficiency. This trend supports repeat usage and product standardization across leading institutions.

Growing Focus on Youth and Low-Risk Patients Drives Targeted Product Development:

Medical professionals increasingly target younger, low-risk patients who prefer non-permanent interventions. These patients prioritize post-procedure flexibility and long-term vascular health. The Global Resorbable Metallic Scaffold (RMS) Market addresses this segment by offering temporary implants that degrade naturally. It provides a safer alternative without compromising structural support during the critical healing window. Product portfolios now include thinner struts and optimized degradation profiles for this demographic. Companies position RMS as a preventive therapy with lower complication risks. Hospitals promote RMS in lifestyle-focused health programs. This segmentation expands the addressable market and improves adoption across private clinics.

Market Challenges Analysis:

High Manufacturing Costs and Complex Design Requirements Limit Mass Scalability:

RMS production involves high-cost raw materials, intricate alloy engineering, and stringent quality control, making cost-efficiency a major hurdle. The Global Resorbable Metallic Scaffold (RMS) Market faces challenges in scaling manufacturing due to precision requirements and mechanical performance standards. It demands advanced fabrication techniques such as micro-tube extrusion, laser cutting, and heat treatment processes. These methods increase capital expenditure and reduce flexibility in mass production. Small and mid-size companies struggle to match economies of scale, limiting broader market entry. High pricing creates reimbursement hurdles in cost-sensitive markets. Health systems hesitate to adopt RMS due to budget constraints. This cost-performance dilemma restricts the pace of commercial expansion.

Uncertainty in Long-Term Clinical Outcomes and Post-Implant Monitoring:

Despite promising short-term results, long-term data on RMS outcomes remain limited, raising concerns among clinicians. The Global Resorbable Metallic Scaffold (RMS) Market must address skepticism from practitioners and payers about device durability and post-implant complications. It lacks extensive multi-year trial data to compare with legacy stents. Variations in degradation timelines and patient responses create outcome inconsistencies. Regulatory agencies require extended follow-up, delaying full market endorsement. Hospitals remain cautious about integrating RMS into standard protocols. Without robust evidence, some clinicians favor well-established stents. This hesitancy hampers RMS penetration, especially in public healthcare systems.

Market Opportunities:

Untapped Emerging Economies Provide Long-Term Growth Pathways for RMS Deployment:

Developing regions across Asia-Pacific, Latin America, and parts of the Middle East represent significant untapped potential for RMS expansion. The Global Resorbable Metallic Scaffold (RMS) Market can benefit from rising healthcare investments and increasing cardiac procedure volumes in these regions. It suits national efforts to modernize cardiovascular care with next-generation technologies. Hospitals in these regions look for scalable and patient-friendly innovations. International collaborations support technology transfer and local manufacturing. This shift aligns with public health goals and creates a new demand base.

Rise in Preventive Cardiology and Personalized Vascular Care Creates Niche Demand:

Cardiology is transitioning toward preventive treatment models that emphasize long-term wellness and vascular regeneration. The Global Resorbable Metallic Scaffold (RMS) Market aligns with these models by offering flexible, temporary implants suited for early-stage intervention. Physicians can tailor treatments using patient-specific diagnostics and resorbable implants. It opens opportunities in personalized care, particularly for low-risk or asymptomatic patients. These applications expand RMS use cases beyond traditional high-risk interventions.

Market Segmentation Analysis:

By Material Type

The Global Resorbable Metallic Scaffold (RMS) Market is segmented by material into magnesium-based, iron-based, and zinc-based scaffolds. Magnesium-based scaffolds lead the segment due to their excellent biocompatibility, mechanical integrity, and controlled degradation, making them suitable for coronary interventions. Iron-based scaffolds offer superior strength but degrade slowly, raising concerns in time-critical procedures. Zinc-based scaffolds present an emerging option with balanced corrosion properties, though they are still in early clinical validation phases. Material choice plays a critical role in performance, healing response, and long-term outcomes.

For instance, Biotronik’s Magmaris scaffold (magnesium-based) is documented to achieve ~95% resorption within 12 months and near-complete endothelialization, as detailed in company technical documents and clinical publications

By Application

The application segment includes Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), and Others. CAD accounts for the largest share due to high global prevalence and demand for temporary vascular support with complete resorption. It aligns with the goal of restoring vessel physiology without permanent implants. PAD is an emerging application area where RMS can provide benefits in treating long, complex lesions. The ‘Others’ segment includes exploratory uses in neurovascular and structural heart interventions, where research is ongoing.

For instance, according to BIOSOLVE-IV registry documents, the vast majority of Magmaris RMS use is in coronary artery disease (CAD) patients, with strong one- and two-year safety and efficacy outcomes

By End User

The end user segment includes Hospitals, Specialty Clinics, and Ambulatory Surgical Centers. Hospitals dominate the market due to their advanced infrastructure, skilled personnel, and ability to conduct complex procedures. Specialty clinics play a growing role in delivering targeted cardiovascular care with efficient patient turnaround. Ambulatory surgical centers are expanding their footprint, especially in urban settings, driven by demand for same-day, minimally invasive treatments. Each end user type contributes to the scalability and accessibility of RMS technologies across healthcare ecosystems.

Resorbable Metallic Scaffold (RMS) Market segmentation

Segmentation:

By Material Type

Magnesium-based Scaffolds
Iron-based Scaffolds
Zinc-based Scaffolds

By Application

Coronary Artery Disease (CAD)
Peripheral Artery Disease (PAD)
Others

By End User

Hospitals
Specialty Clinics
Ambulatory Surgical Centers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Regional Analysis:

North America

The North America Resorbable Metallic Scaffold (RMS) Market size was valued at USD 55.53 million in 2018 to USD 86.02 million in 2024 and is anticipated to reach USD 158.88 million by 2032, at a CAGR of 7.4% during the forecast period. North America holds approximately 29% of the Global Resorbable Metallic Scaffold (RMS) Market share. It benefits from high healthcare expenditure, strong interventional cardiology infrastructure, and widespread adoption of next-generation devices. The United States leads regional demand, driven by early approvals, physician familiarity, and favorable reimbursement pathways. Hospitals and academic institutions actively participate in clinical trials and post-market studies, reinforcing innovation. Key companies in the region invest in proprietary magnesium-based technologies for improved outcomes. Rising incidence of coronary artery disease continues to push demand for minimally invasive and bioresorbable solutions. It remains a key region for RMS launches and first-to-market strategies.

Europe

The Europe Resorbable Metallic Scaffold (RMS) Market size was valued at USD 80.59 million in 2018 to USD 123.75 million in 2024 and is anticipated to reach USD 218.93 million by 2032, at a CAGR of 6.8% during the forecast period. Europe accounts for about 40% of the Global Resorbable Metallic Scaffold (RMS) Market share, the largest among all regions. Countries such as Germany, France, and the UK drive growth with robust medical device regulations and widespread public healthcare access. The region supports early adoption of innovative cardiovascular solutions backed by structured reimbursement policies. It also benefits from strong collaborations between academic research centers and device manufacturers. Physicians increasingly prefer RMS for younger and low-risk patients needing non-permanent solutions. Regulatory agencies maintain close oversight, ensuring safety and clinical performance. It continues to be a key geography for clinical validation and long-term deployment.

Asia Pacific

The Asia Pacific Resorbable Metallic Scaffold (RMS) Market size was valued at USD 34.84 million in 2018 to USD 59.58 million in 2024 and is anticipated to reach USD 124.65 million by 2032, at a CAGR of 9.1% during the forecast period. Asia Pacific captures roughly 23% of the Global Resorbable Metallic Scaffold (RMS) Market share. It shows the fastest growth rate due to rising healthcare infrastructure, high cardiovascular disease burden, and expanding access to minimally invasive treatments. China, Japan, India, and South Korea contribute significantly to regional expansion. Governments invest in local manufacturing and research to reduce dependence on imports. Hospitals adopt RMS solutions as part of broader modernization efforts in tertiary care. Increasing awareness of advanced cardiology procedures drives both urban and semi-urban demand. It presents untapped opportunities for device makers targeting volume-driven growth.

Latin America

The Latin America Resorbable Metallic Scaffold (RMS) Market size was valued at USD 9.24 million in 2018 to USD 14.36 million in 2024 and is anticipated to reach USD 23.50 million by 2032, at a CAGR of 5.8% during the forecast period. Latin America holds around 4% of the Global Resorbable Metallic Scaffold (RMS) Market share. Brazil and Mexico lead in regional demand, supported by their growing interventional cardiology sectors and emerging healthcare infrastructure. Access to innovative cardiovascular devices improves as private healthcare facilities upgrade treatment capabilities. Market entry is facilitated through partnerships with local distributors and targeted awareness campaigns. Regulatory frameworks are evolving but remain variable across countries. Clinical adoption progresses slower due to pricing pressures and reimbursement challenges. It shows long-term potential for RMS penetration as access improves and procedures become more standardized.

Middle East

The Middle East Resorbable Metallic Scaffold (RMS) Market size was valued at USD 4.95 million in 2018 to USD 7.08 million in 2024 and is anticipated to reach USD 10.85 million by 2032, at a CAGR of 4.9% during the forecast period. The region accounts for nearly 2% of the Global Resorbable Metallic Scaffold (RMS) Market share. The Gulf Cooperation Council (GCC) countries drive demand with investments in premium healthcare infrastructure and medical tourism. UAE and Saudi Arabia serve as hubs for advanced cardiovascular procedures. Hospitals in these countries explore RMS use in younger patient groups seeking non-permanent solutions. The region remains highly import-dependent, limiting widespread access. Policy reforms and public-private partnerships may improve procurement of high-end devices. It offers steady but niche growth potential tied to premium segments.

Africa

The Africa Resorbable Metallic Scaffold (RMS) Market size was valued at USD 2.94 million in 2018 to USD 5.10 million in 2024 and is anticipated to reach USD 7.49 million by 2032, at a CAGR of 4.3% during the forecast period. Africa contributes around 1% of the Global Resorbable Metallic Scaffold (RMS) Market share. South Africa leads in regional adoption due to its relatively developed healthcare sector and access to interventional cardiology. Broader market development is hindered by limited healthcare infrastructure, lack of specialized personnel, and high device costs. Public hospitals focus on essential cardiac services, delaying adoption of advanced RMS technologies. Private healthcare providers in select urban regions may gradually introduce RMS in high-income segments. International aid programs and public health initiatives could support future device penetration. It remains a low-volume but strategically relevant region for long-term outreach.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis:

Abbott Laboratories
Biotronik
Elixir Medical Corporation
MicroPort Scientific Corporation
AMG International GmbH
Boston Scientific Corporation
Alvimedica
Lepu Medical Technology
REVA Medical, Inc.
Arterius Ltd.

Competitive Analysis:

The Global Resorbable Metallic Scaffold (RMS) Market features a moderately concentrated landscape with a few dominant players leading innovation and commercialization. Companies such as Abbott Laboratories, Boston Scientific, Elixir Medical, Biotronik, and MicroPort Scientific focus on next-generation magnesium-based scaffolds and invest heavily in R&D and clinical validation. These firms maintain strong distribution networks, strategic collaborations, and early regulatory approvals in key markets. Emerging players like Arterius Ltd. and AMG International are developing niche products targeting performance optimization and cost efficiency. It faces high entry barriers due to strict regulatory requirements, complex manufacturing, and high capital investment, allowing established firms to maintain a competitive edge.

Recent Developments:

In April 2024, Abbott received FDA approval for its Esprit BTK Resorbable Scaffold System, the first approved dissolving stent specifically for below-the-knee (BTK) arteries in patients with peripheral artery disease. The device provides temporary vascular scaffolding with a radial strength similar to metallic stents, integrating everolimus drug elution. Clinical trial data, published in The New England Journal of Medicine, demonstrated significantly better patient outcomes compared to traditional angioplasty, paving the way for U.S. commercialization and expanded clinical adoption.
In October 2023, Elixir Medical showcased the DESolve NXT Plus System at TCT, integrating the novel TRANSFORM Balloon Technology. Live demonstrations highlighted enhanced deliverability and long-term conformability, affirming the system’s ability to match leading drug-eluting stents while expanding platform innovation for complex coronary anatomies. Elixir reported continuing investment in broadening its bioresorbable scaffold portfolio.
In 2025, Lepu Medical advanced its NeoVas bioresorbable scaffold—a sirolimus-eluting PLLA platform—continuing international multicenter clinical trials. Prior studies confirmed the NeoVas Scaffold to be noninferior to metallic drug-eluting stents regarding late lumen loss and angina rates, establishing safety and efficacy for coronary use in a cohort exceeding 500 patients

Market Concentration & Characteristics:

The Global Resorbable Metallic Scaffold (RMS) Market exhibits moderate concentration, dominated by a handful of multinational corporations with proven clinical pipelines. It reflects a technology-intensive environment requiring high R&D investment and adherence to stringent regulatory pathways. Competitive advantage stems from product performance, physician training programs, and early market access. Entry for new firms remains challenging without strategic collaborations or proprietary material technologies. It also shows gradual adoption cycles due to the cautious approach of healthcare providers regarding newer implant technologies.

Report Coverage:

The research report offers an in-depth analysis based on Material Type, End User and Application. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

Adoption of magnesium-based scaffolds will accelerate due to favorable clinical outcomes and material advancements.
Coronary artery disease will continue to be the dominant application segment, supported by rising global prevalence.
Hospitals will maintain the largest end-user share, driven by complex procedures and advanced infrastructure.
Asia Pacific will emerge as a key growth region due to improving access, local manufacturing, and expanding patient base.
Manufacturers will focus on optimizing scaffold degradation rates to align with specific therapeutic windows.
Integration of AI-driven imaging and real-time diagnostics will improve scaffold placement and patient monitoring.
Strategic partnerships between medical institutions and device makers will strengthen product validation pipelines.
Clinical trials will continue to expand across Europe and North America to secure long-term safety data.
Regulatory support will favor innovative RMS platforms with proven efficacy and low complication risks.
Rising demand for personalized vascular care will open new opportunities for niche RMS products.

CHAPTER NO. 1: GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2: EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3: RESORBABLE METALLIC SCAFFOLD (RMS) MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend
3.6.2 Price Trend by Product

CHAPTER NO. 4: KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Product Categories

4.3 Application Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Material Type & End User Revenue

CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS

6.1. Import Analysis by Region

6.1.1. Global Resorbable Metallic Scaffold (RMS) Import Revenue By Region

6.2. Export Analysis by Region

6.2.1. Global Resorbable Metallic Scaffold (RMS) Export Revenue By Region

CHAPTER NO. 7: COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Resorbable Metallic Scaffold (RMS): Company Market Share

7.2. Global Resorbable Metallic Scaffold (RMS) Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8: RESORBABLE METALLIC SCAFFOLD (RMS) MARKET – BY MATERIAL TYPE SEGMENT ANALYSIS

8.1. Resorbable Metallic Scaffold (RMS) Overview by Material Type Segment

8.1.1. Resorbable Metallic Scaffold (RMS) Revenue Share By Material Type

8.2. Magnesium-based Scaffolds

8.3. Iron-based Scaffolds

8.4. Zinc-based Scaffolds

CHAPTER NO. 9: RESORBABLE METALLIC SCAFFOLD (RMS) MARKET – BY APPLICATION SEGMENT ANALYSIS

9.1. Resorbable Metallic Scaffold (RMS) Overview by Application Segment

9.1.1. Resorbable Metallic Scaffold (RMS) Revenue Share By Application

9.2. Coronary Artery Disease (CAD)

9.3. Peripheral Artery Disease (PAD)

9.4. Others

CHAPTER NO. 10: RESORBABLE METALLIC SCAFFOLD (RMS) MARKET – BY END USER SEGMENT ANALYSIS

10.1. Resorbable Metallic Scaffold (RMS) Overview by End User Segment

10.1.1. Resorbable Metallic Scaffold (RMS) Revenue Share By End User

10.2. Hospitals

10.3. Specialty clinics

10.4. Ambulatory surgical centers

CHAPTER NO. 11: RESORBABLE METALLIC SCAFFOLD (RMS) MARKET – REGIONAL ANALYSIS

11.1. Resorbable Metallic Scaffold (RMS) Overview by Region Segment

11.1.1. Global Resorbable Metallic Scaffold (RMS) Revenue Share By Region

11.1.2. Regions

11.1.3. Global Resorbable Metallic Scaffold (RMS) Revenue By Region

11.1.4. Material Type

11.1.5. Global Resorbable Metallic Scaffold (RMS) Revenue By Material Type

11.1.6. Application

11.1.7. Global Resorbable Metallic Scaffold (RMS) Revenue By Application

11.1.8. End User

11.1.9. Global Resorbable Metallic Scaffold (RMS) Revenue By End User

CHAPTER NO. 12: NORTH AMERICA RESORBABLE METALLIC SCAFFOLD (RMS) MARKET – COUNTRY ANALYSIS

12.1. North America Resorbable Metallic Scaffold (RMS) Overview by Country Segment

12.1.1. North America Resorbable Metallic Scaffold (RMS) Revenue Share By Region

12.2. North America

12.2.1. North America Resorbable Metallic Scaffold (RMS) Revenue By Country

12.2.2. Material Type

12.2.3. North America Resorbable Metallic Scaffold (RMS) Revenue By Material Type

12.2.4. Application

12.2.5. North America Resorbable Metallic Scaffold (RMS) Revenue By Application

12.2.6. End User

12.2.7. North America Resorbable Metallic Scaffold (RMS) Revenue By End User

2.3. U.S.

12.4. Canada

12.5. Mexico

CHAPTER NO. 13: EUROPE RESORBABLE METALLIC SCAFFOLD (RMS) MARKET – COUNTRY ANALYSIS

13.1. Europe Resorbable Metallic Scaffold (RMS) Overview by Country Segment

13.1.1. Europe Resorbable Metallic Scaffold (RMS) Revenue Share By Region

13.2. Europe

13.2.1. Europe Resorbable Metallic Scaffold (RMS) Revenue By Country

13.2.2. Material Type

13.2.3. Europe Resorbable Metallic Scaffold (RMS) Revenue By Material Type

13.2.4. Application

13.2.5. Europe Resorbable Metallic Scaffold (RMS) Revenue By Application

13.2.6. End User

13.2.7. Europe Resorbable Metallic Scaffold (RMS) Revenue By End User

13.3. UK

13.4. France

13.5. Germany

13.6. Italy

13.7. Spain

13.8. Russia

13.9. Rest of Europe

CHAPTER NO. 14: ASIA PACIFIC RESORBABLE METALLIC SCAFFOLD (RMS) MARKET – COUNTRY ANALYSIS

14.1. Asia Pacific Resorbable Metallic Scaffold (RMS) Overview by Country Segment

14.1.1. Asia Pacific Resorbable Metallic Scaffold (RMS) Revenue Share By Region

14.2. Asia Pacific

14.2.1. Asia Pacific Resorbable Metallic Scaffold (RMS) Revenue By Country

14.2.2. Material Type

14.2.3. Asia Pacific Resorbable Metallic Scaffold (RMS) Revenue By Material Type

14.2.4. Application

14.2.5. Asia Pacific Resorbable Metallic Scaffold (RMS) Revenue By Application

14.2.5. End User

14.2.7. Asia Pacific Resorbable Metallic Scaffold (RMS) Revenue By End User

14.3. China

14.4. Japan

14.5. South Korea

14.6. India

14.7. Australia

14.8. Southeast Asia

14.9. Rest of Asia Pacific

CHAPTER NO. 15: LATIN AMERICA RESORBABLE METALLIC SCAFFOLD (RMS) MARKET – COUNTRY ANALYSIS

15.1. Latin America Resorbable Metallic Scaffold (RMS) Overview by Country Segment

15.1.1. Latin America Resorbable Metallic Scaffold (RMS) Revenue Share By Region

15.2. Latin America

15.2.1. Latin America Resorbable Metallic Scaffold (RMS) Revenue By Country

15.2.2. Material Type

15.2.3. Latin America Resorbable Metallic Scaffold (RMS) Revenue By Material Type

15.2.4. Application

15.2.5. Latin America Resorbable Metallic Scaffold (RMS) Revenue By Application

15.2.6. End User

15.2.7. Latin America Resorbable Metallic Scaffold (RMS) Revenue By End User

15.3. Brazil

15.4. Argentina

15.5. Rest of Latin America

CHAPTER NO. 16: MIDDLE EAST RESORBABLE METALLIC SCAFFOLD (RMS) MARKET – COUNTRY ANALYSIS

16.1. Middle East Resorbable Metallic Scaffold (RMS) Overview by Country Segment

16.1.1. Middle East Resorbable Metallic Scaffold (RMS) Revenue Share By Region

16.2. Middle East

16.2.1. Middle East Resorbable Metallic Scaffold (RMS) Revenue By Country

16.2.2. Material Type

16.2.3. Middle East Resorbable Metallic Scaffold (RMS) Revenue By Material Type

16.2.4. Application

16.2.5. Middle East Resorbable Metallic Scaffold (RMS) Revenue By Application

16.2.6. End User

16.2.7. Middle East Resorbable Metallic Scaffold (RMS) Revenue By End User

16.3. GCC Countries

16.4. Israel

16.5. Turkey

16.6. Rest of Middle East

CHAPTER NO. 17: AFRICA RESORBABLE METALLIC SCAFFOLD (RMS) MARKET – COUNTRY ANALYSIS

17.1. Africa Resorbable Metallic Scaffold (RMS) Overview by Country Segment

17.1.1. Africa Resorbable Metallic Scaffold (RMS) Revenue Share By Region

17.2. Africa

17.2.1. Africa Resorbable Metallic Scaffold (RMS) Revenue By Country

17.2.2. Material Type

17.2.3. Africa Resorbable Metallic Scaffold (RMS) Revenue By Material Type

17.2.4. Application

17.2.5. Africa Resorbable Metallic Scaffold (RMS) Revenue By Application

17.2.6. End User

17.2.7. Africa Resorbable Metallic Scaffold (RMS) Revenue By End User

17.3. South Africa

17.4. Egypt

17.5. Rest of Africa

CHAPTER NO. 18: COMPANY PROFILES

18.1. Abbott Laboratories

18.1.1. Company Overview

18.1.2. Product Portfolio

18.1.3. Financial Overview

18.1.4. Recent Developments

18.1.5. Growth Strategy

18.1.6. SWOT Analysis

18.2. Biotronik

Pipeline Companies

18.3. Elixir Medical Corporation

18.4. MicroPort Scientific Corporation

18.5. AMG International GmbH

18.6. Boston Scientific Corporation

18.7. Alvimedica

18.8. Lepu Medical Technology

18.9. REVA Medical, Inc.

18.10. Arterius Ltd.

Frequently Asked Questions

What is the current market size for Global Resorbable Metallic Scaffold (RMS) Market, and what is its projected size in 2032?

The Global RMS Market was valued at USD 188.09 million in 2018 and reached USD 295.89 million in 2024. It is projected to grow to USD 544.29 million by 2032.

Which Global Resorbable Metallic Scaffold (RMS) Market segment held the largest share in 2024?

Coronary Artery Disease (CAD) held the largest market share in 2024 due to high procedure volume and clinical suitability for RMS use.

What are the primary factors fueling the growth of the Global Resorbable Metallic Scaffold (RMS) Market?

Growth is driven by rising cardiac cases, aging populations, R&D in magnesium-based scaffolds, and awareness of non-permanent stenting benefits.

Who are the leading companies in the Global Resorbable Metallic Scaffold (RMS) Market?

Key players include Abbott Laboratories, Boston Scientific, Biotronik, Elixir Medical, MicroPort Scientific, and AMG International GmbH.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Reviewed By
Gunakesh Parmar

Research Consultant

With over 15 years of dedicated experience in market research since 2009, specializes in delivering actionable insights from data.

View Profile

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$12699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –